Thumbs Up All Around for Danaher Purchase of Life Tech, MDS' Mass Spec Business

The prevailing view from Wall Street is that the sale of the ABI/MDS mass spectrometry business could provide a boost for all parties concerned. According to one analyst, the transaction "resolves an area of uncertainty in Life's portfolio and helps shore up the balance sheet."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.